Physician profile
Jonathan E Krichev
NPI 1407807621
$9,231.02
in general payments reported to CMS, 2019-2025
36 companies · $717 in 2025
The $717 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,549 · 2021: $2,008 · 2022: $1,582 · 2023: $1,223 · 2024: $993 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,204.78 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $882.98 | 2019-2025 | |
| Lilly USA, LLC | $739.32 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $665.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $651.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lundbeck LLC | $314.22 | 2022-2025 | Vyepti |
| Amgen INC. | $310.33 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $310.02 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $306.55 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.73 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $278.22 | 2019-2021 | |
| Abbvie INC. | $276.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.16 | 2020-2023 | Tradjenta, Trijardy Xr, Synjardy |
| Phathom Pharmaceuticals, INC. | $249.42 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $200.79 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $180.77 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $166.33 | 2022 | |
| Abbott Laboratories | $136.44 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $130.24 | 2020-2021 | |
| Eisai INC. | $128.73 | 2020-2021 | |
| Allergan, INC. | $85.75 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $78.59 | 2019-2023 | Livalo |
| Teva Pharmaceuticals USA, INC. | $68.39 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $57.39 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $47.89 | 2021 | |
| Philips North America LLC | $31.42 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Zimmer Biomet Holdings, INC. | $27.78 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Sanofi Pasteur INC. | $23.77 | 2023 | |
| Bioventus LLC | $23.13 | 2019 | |
| Ibsa Pharma INC. | $17.92 | 2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $17.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.71 | 2020 | |
| Depuy Synthes Sales INC. | $15.38 | 2023 | Monovisc |
| Axsome Therapeutics, INC. | $15.28 | 2025 | Auvelity |
| Gilead Sciences, INC. | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Krichev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.